Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

HUTCHMED (China) Limited (HCM)

19.87   0.04 (0.2%) 01-27 16:00
Open: 19.75 Pre. Close: 19.83
High: 20.08 Low: 19.4801
Volume: 375,955 Market Cap: 3,437(M)

Technical analysis

as of: 2023-01-27 4:45:06 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 24.85     One year: 29.03
Support: Support1: 16.65    Support2: 13.8
Resistance: Resistance1: 21.28    Resistance2: 24.85
Pivot: 17.67
Moving Average: MA(5): 18.88     MA(20): 17.34
MA(100): 12.16     MA(250): 14.19
MACD: MACD(12,26): 1.3     Signal(9): 1.1
Stochastic oscillator: %K(14,3): 75.6     %D(3): 72.8
RSI: RSI(14): 70.2
52-week: High: 28.39  Low: 7.38
Average Vol(K): 3-Month: 614 (K)  10-Days: 315 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ HCM ] has closed above the upper band by 4.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.1 - 20.18 20.18 - 20.26
Low: 19.28 - 19.37 19.37 - 19.46
Close: 19.72 - 19.86 19.86 - 20

Company Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Headline News

Sun, 29 Jan 2023
HCM City to improve management capacity by better surveillance ... - VietNamNet

Fri, 27 Jan 2023
Asahi Life Asset Management CO. LTD. Takes $123000 Position in ... - MarketBeat

Fri, 27 Jan 2023
Brinker Capital Investments LLC Makes New Investment in Paycor ... - MarketBeat

Thu, 26 Jan 2023
Waco Go Red Event Raising Awareness for Heart Diseases like HCM - MarketScale

Wed, 25 Jan 2023
Will HUTCHMED (China) Ltd (HCM) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Tue, 24 Jan 2023
A Cardiac Magnetic Resonance Study: Comparison of Biventricular ... - Cureus

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 173 (M)
Shares Float 88 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 23.5 (%)
Shares Short 1,640 (K)
Shares Short P.Month 2,520 (K)

Stock Financials

EPS -1.24
EPS Est Next Qtl 0
EPS Est This Year -0.06
EPS Est Next Year -0.13
Book Value (p.s.) 4.73
Profit Margin (%) -63.7
Operating Margin (%) -95.2
Return on Assets (ttm) -19.4
Return on Equity (ttm) -24.8
Qtrly Rev. Growth 33.2
Gross Profit (p.s.) -1.17
Sales Per Share 2.31
EBITDA (p.s.) -2.16
Qtrly Earnings Growth 0
Operating Cash Flow -223 (M)
Levered Free Cash Flow -162 (M)

Stock Valuations

PE Ratio -16.16
PEG Ratio 0
Price to Book value 4.19
Price to Sales 8.57
Price to Cash Flow -15.43

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.